Cardiology 2 Flashcards

Recall

1
Q

Diseases presenting with high output HF (8)

A

Thyrotoxicosis
Obesity
Anemia
Beri beri
Myeloproliferative disorder
Chronic lung disease
Arteriovenous shunt
Cirrhosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Most common cause of high output HF

A

obesity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Target resting heart rate range in chronic HF on GDMT

A

<70-75bpm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Abdominojugular test mechanism

A

Increase in right atrial pressure during 10 s of firm midabdominal compression followed by an abrupt drop on pressure release, suggests elevated left-sided filling pressures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pathophysiologic link between sleep apnea and heart failure

A

Decreased preload
Increased afterload
Intermittent hypoxia
Sympathetic activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Preferred drugcombination as a disease-modifying approach in HFrEF if unable to tolerate RAAS-based therapy

A

Hydralazine + nitrates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Contraindication of ARNI for HF

A

With prior history of angioedema

Note: If transitioning from ACEi, give ARNI with 36 hour gap to limit risk of overlap

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Antiarrhythmic drug therapy preferred for atrial arrhythmias in HF

A

Amiodarone and Dofetilide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Appropriate candidates for ICD prophylactic therapy

A

NYHA II or III and LVEF < 35% irrespective of etiology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Single most important associated of extent of dyssynchrony

A

Widened QRS interval, particularly in the presence of a left bundle branch blck pattern

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ECG findings in px that would benefit from CRT placement

A

QRS width of >149ms and a left bundle branch block pattern

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MRA should be withdrawn how many weeks before measuring PA/PRA in work up for secondary hypertension

A

4-6 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Two most common causes of sporadic primary aldosteronism

A

Aldosterone producing adenoma and bilateral adrenal hyperplacia

Tumor is most often unilateral, measures <3cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

BP lowering strategy in hypertensive urgency

A

By 25% of the initial value over 24h

IF with encephalopathy: reduce MAP by no more than 25% within MINUTES or 2 hours to a BP range of 160/100-110
Drug choice: IV nitroprusside; labetalol, nicardipine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Definition of SEVERE LV outflow obstruction in AS

A

mean systolic pressure gradient >40mmHg with a normal cardiac output or
aortic orifice area <1cm2

Moderate AS: valve area 1-1.5cm2
Mild AS: valve area 1.5-2cm2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Cardinal symptoms of AS

A

exertional dyspnea, angina pectoris, syncope

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Murmur of AS

A

Low pitched, rough, rasping
Loudest at the base of the heart
Most commonly in 2nd right ICS
Tramitted along the carotid arteries, occasionally downward and to the apex

Ejection (mid) sIystolic murmur that commences shortly after the S1, increases in intensity to reach a peak toward the middle of ejection, and ends just before aortic valve closure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Indications for surgical treatment in AS

A

Severe AS (<1cm2 area or 0.6cm2/2 body surface area) who are symptomatic

Exhibit LV systolic dysfunction (EF<50%)

AS due to BAV disease and aneurysmal root or ascending aorta (max dimension >5.5cm)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Operation for aneurysm disease recommended

A

At small aortic diameters (4.5-5cm) with family history of an aortic catastrophe or
Rapid aneurysm growth (>0.5cm/year)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Murmur of aortic regurgitation

A

High-pitched, blowing, decrescendo diastolic murmur, heard best in the third intercostal space along the left sternal border

In isolated AR - mid systolic ejection murmur frequently audible (base of the heart and transmitted along the carotids)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Murmur in severe AR described a soft, low pitched, rumbling mid to late diastolic
Produced by diastolic displacement of the ANTERIOR leaflet of the mitral valve by the AR streatm

A

Austin Flint murmur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Characteristic echo finding in AR

A

Rapid, high-frequency diastolic fluttering of the anterior mitral leaflet produced by the impact of the regurgitant jet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Hemodynamic hallmark of MS

A

Abnormally elevated left atrioventricular pressure gradient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Definition of severe MS

A

<1.5cm2 orifice area

very severe: <1cm2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Murmur of MS

A

Opening snap os the mitral valve most readily audible in expiration at or just medial to the cardiac apex
Followed by low pitched rumbling diastolic murmur heard best at the apex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Eponym for a functional TR murmur that is due to pulmonary hypertension in MS

(pansystolic murmur produced by a functional TR that may be audible at the left sternal border, louder during inspiration and diminishes during forced expiration)

A

Carvallo’s sign

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

High pitched diastolic descresndo blowing murmur along the left sternal border that results from dilation of the PULMONARY valve ring (occurs in px with MITRAL valve disease and severe pulmonary hypertension)

A

Graham Steel murmur

28
Q

MR associated with HOCM is dependent on:

A

systolic ANTERIOR motion of the ANTERIOR mitral valve into a narrowed LV outflow tract

29
Q

Chronic severe MR is progressive due to

A

enlargement of LA places tension on POSTERIOR mitral valve leaflet

30
Q

Murmur of MR

A

Most characteristic of chronic severe MR: systolic murmur at least grade III/IV, holosystolic, decrescendo and ceases in mid to late systole
Prominent at the apex and radiates to axilla
Wide but physiologic splitting of S2
Low pitched S3 after closure of aortic valve
Short rumbling mid-diastolic murmur
S4 often audible in patients with ACUTE severe MR

31
Q

Severe PS defined by

A

Peak systolic gradient across the pulmonic valve of > 64mmHg (jet velocity >4m/s)

Moderate PS: 36-64mmHg (jet velocity 3-4m/s)
Mild PS <36mmHg (jet velocity <3m/s)

32
Q

Hallmark of PR (PE)

A

High pitched decresendo diastolic murmur (Graham Steel) heard along the left sternal border - louder on inspiration

33
Q

Common causes of HF with preserved EF

A

Aging, obesity, hypertension

34
Q

Conditions that result to concentric hypertrophy (consequence of pressure overload)

A

Hypertension and AS

vs eccentric hypertrophy d/t volume overload - MR and AR

35
Q

Microbial etiologies of nosocomial PVE (within 2 months of valve surgery)

A

S. aureus, CoNS, facultative gram-negative bacilli, diphtheroids, and fungi

36
Q

Lifestyle Modifications to Manage Hypertension

A
  1. Weight reduction: BMI <25 kg/m2
  2. Dietary salt reduction: <6 g NaCl/d
  3. Moderation of alcohol consumption: ≤2 drinks/d in men and ≤1 drink/d in women
  4. Adapt DASH-type dietary plan: Diet rich in fruits, vegetables, and low-fat dairy products with reduced content of saturated and total fat. Diet is also rich in potassium, calcium, and magnesium.
  5. Physical activity: Regular aerobic activity, e.g., brisk walking for 30 min/d
37
Q

Initial goal of therapy in malignant hypertension

A

reduce mean arterial blood pressure by no more than 25% within minutes to 2 h or to a blood pressure in the range of 160/100–110 mmHg

38
Q

Most common gas exchange abnormalities in Pulmonary Embolism

A

arterial hypoxemia and an increased alveolar-arterial O2 tension gradient

39
Q

Chest radiographic findings in pulmonary embolism

A
  • focal oligemia (Westermark’s sign)
  • peripheral wedge-shaped density usually located at the pleural base (Hampton’s hump)
  • enlarged right descending pulmonary artery (Palla’s sign).
39
Q

Most frequent cited ECG abnormality in pulmonary embolism

A

sinus tachycardia; S1Q3T3 sign: an S wave in lead I, a Q wave in lead III, and an inverted T wave in lead III

39
Q

Effective anticoagulation strategies in venous thromboembolism

A
  1. waning strategy: parenteral anticoagulation with unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), or fondaparinux “bridged” to warfarin
  2. parenteral therapy, switched after 5 days to a novel oral anticoagulant such as dabigatran (a direct thrombin inhibitor) or edoxaban (an anti-Xa agent)
  3. oral anticoagulation monotherapy with rivaroxaban or apixaban (both are anti-Xa agents) with a 3-week or 1-week load- ing dose, respectively, followed by a maintenance dose

***For patients with VTE in the setting of suspected or proven heparin-induced thrombocytopenia, one can choose between two parenteral direct thrombin inhibitors: argatroban and bivalirudin

40
Q

Best-known indirect sign of PE on transthoracic echocardiography

A

McConnell’s sign: hypokinesis of the RV free wall with normal or hyperkinetic motion of the RV apex

41
Q

Non cardiac causes of elevated BNP levels

A

advanced age, female sex, CKD

42
Q

Condition that will give FALSELY LOW NT-pro BNP

A

Obesity

43
Q

Treatment for patients unable to tolerate RAAS-based therapy in HFrEF

A

Hydralazine + Nitrates

44
Q

Subset of patients with HFrEF that will benefit most from cardiac resynchronization therapy? (CRT)

A

Most benefit in mildly symptomatic HFrEF patients accrues from applying this therapy in those with a QRS width of >149 ms and a left bundle branch block pattern.

**Cardiac Resynchronization in Heart Failure Study (CARE-HF) trial was the first study to demonstrate a reduction in all- cause mortality with CRT placement in patients with HFrEF on opti- mal therapy with continued moderate-to-severe residual symptoms of NYHA class III or IV HF.

45
Q

First line agents in reducing severity of obstruction in HOCM

A

Beta blockers and calcium channel blockers

46
Q

Risk factors for postpartum cardiomyopathy

A

increased maternal age
increased parity
twin pregnancy
malnutrition
use of tocolytic therapy for premature labor
preeclampsia or toxemia of pregnancy

47
Q

Preferred anti arrythmic agents for HCOM

A

Disopyramide and Amiodarone

48
Q

Medication that should be avoided in HCOM

A

Digitalis glycosides

49
Q

Maneuvers that intensify murmur of mitral valve prolapse?

A

Sudden standing and strain phase of valsalva

49
Q

Chemotherapeutic agent that produces myocardial damage by causing recurrent coronary artery spasm leading to decreased myocardial contractility

A

5-FU, Cisplatin and other alkylating agents

50
Q

Test to differentiate true severe AS (with a fixed small valve area) from pseudosevere AS (with a functionally small valve area due to severely LV systolic dysfunction)

A

low-dose dobutamine stress transthoracic echocardiography

51
Q

Major determinants of myocardial oxygen demand

A

heart rate
myocardial contractility
myocardial wall tension

52
Q

Determinant for adequate supply of oxygen

A

level of oxygen carrying capacity of blood determined by inspired oxygen, pulmonary function and hemoglobin concentration; level of coronary flow

53
Q

Contraindications to exercise stress testing

A

rest angina within 48 h
unstable rhythm
severe aortic stenosis
acute myocarditis
uncontrolled heart failure
severe pulmonary hypertension
active infective endocarditis.

54
Q

Suggestive of severe IHD during stress test

A

development of angina and/or severe (>0.2 mV) ST-segment depression at a low workload, i.e., before completion of stage II of the Bruce protocol, and/or ST- segment depression that persists >5 min after the termination of exercise

55
Q

Clear contraindications to the use of fibrinolytic agents

A
  • history of cerebrovascular hemorrhage at any time
  • a nonhemorrhagic stroke or other cerebrovascular event within the past year
  • marked hypertension (a reliably determined systolic arterial pressure >180 mmHg and/or a diastolic pressure >110 mmHg) at any time during the acute presentation
  • suspicion of aortic dissection
  • active internal bleeding (excluding menses)
56
Q

TIMI risk score for NSTE-ACS (7)

A
  1. age >65 yrs
  2. known CAD (>50% stenosis)
  3. ST deviation >0.5mm on presenting ECG
  4. increased cardiac markers
  5. > 2 original episodes in prior 24hrs
  6. prior angina
  7. > 3 CAD risk factors.

he case above has 3 of these risk markers and thus has a 13% (high risk) 14-days risk of death, new or recurrent MI or severe recurrent ischemia requiring urgent revascularization.

56
Q

Relative contraindications to fibrinolytic therapy

A
  • current use of anticoagulants (international normalized ratio ≥2)
  • recent (<2 weeks) invasive or surgical procedure
  • prolonged (>10 min) cardiopulmonary resuscitation
  • known bleeding diathesis
  • pregnancy
  • hemorrhagic ophthalmic condition (e.g., hemorrhagic diabetic retinopathy)
  • active peptic ulcer disease
  • history of severe hypertension that is currently adequately controlled
57
Q

Modified Duke Criteria for the Clinical Diagnosis of Infective Endocarditis

A

MAJOR:
1. Positive blood culture (two separate blood cultures)
OR
Persistently positive blood culture (blood cultures drawn >12 h apart; or all of 3 or a majority of ≥4 separate blood cultures, with first and last drawn at least 1 h apart
OR
Single positive blood culture for Coxiella burnetii or phase I IgG antibody titer of >1:800

  1. Evidence of endocardial involvement

MINOR

  1. Predisposition: predisposing heart conditions or injection drug use
  2. Fever ≥38.0°C (≥100.4°F)
  3. Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, Janeway lesions
  4. Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth’s spots, rheumatoid factor
  5. Microbiologic evidence: positive blood culture but not meeting major criterion, as noted previously,d or serologic evidence of active infection with an organism consistent with infective endocarditis
58
Q

Organisms Causing Major Clinical Forms of Infective Endocarditis (IE)

A

Native Valve Community-Acquired IE: Streptococci
Native Valve Health Care Associated IE: Staph aureus

Prostatic valve IE <2 months: CONS
Prostatic valve IE 2-12 months: CONS
Prostatic valve IE >12 months: Streptococci

TAPVR PVE: Enterococci –> S. aures –> CONS

CIED IE: CONS

59
Q

Indications for cardiac surgery in endocarditis

A

A. Surgery REQUIRED
- Moderate or severe congestive heart failure or shock due to valve dysfunction
- Paravalvular extension of infection with abscess, fistula, or heart block
- Persistent bacteremia without an extracardiac cause despite 7–10 days of optimal antimicrobial therapy
- Lack of effective antimicrobial therapy (e.g., fungal, Brucella, multidrug-resistant gram-negative bacillary endocarditis)
- Partially dehisced unstable prosthetic valve
- Paravalvular extension of infection with abscess, fistula, or heart block

60
Q

Class I recommendation for permanent pacing in AV blocks

A
  1. Complete heart block (acquired)
  2. Advanced AV block
  3. Mobitz Type II
  4. Evidence for infranodal block
  5. Neuromuscular disease associated with progressive conduction tissue disorder
61
Q

Class I indications for catheter ablation in symptomatic atrial fibrillation

A
  1. Paroxysmal or persistent AF and heart failure with reduced EF
  2. Persistent AF with FAILED drug therapy